Siglec-6 Identified as Drug Target for Chronic Lymphocytic Leukemia

Share this content:
Cell surface antigen Siglec-6 was broadly expressed in chronic lymphocytic leukemia after transplantation, suggesting a new potential drug target.
Cell surface antigen Siglec-6 was broadly expressed in chronic lymphocytic leukemia after transplantation, suggesting a new potential drug target.

Cell surface antigen Siglec-6 was broadly expressed in chronic lymphocytic leukemia (CLL) post allogeneic hematopoietic stem cell transplantation (post-alloHSCT), suggesting a new potential target for antibody-based therapeutics.1 Although patients with CLL have a 5-year survival rate of more than 80%, alloHSCT is the only curative treatment and new monoclonal antibody drugs and targets are needed. The study findings were recently published in Cancer Immunology Research.

To identify a possible monoclonal antibody drug target, researchers first tapped into a platform they had previously developed to mine the antibody repertoire of patients who responded to alloHSCT and used a group of highly homologous monoclonal antibodies shown to bind to the same unknown CLL cell surface antigen.

Through next-generation sequencing of cDNAs encoding variable heavy-chain domains, the study authors wrote, they showed that these monoclonal antibodies had a relative abundance of approximately 0.1% in the post-alloHSCT antibody repertoire and were enriched approximately 1000-fold after 3 rounds of selection on primary CLL cells.

Using RNA-seq and cell microarray screening technology, the unknown CLL cell surface antigen was identified as Siglec-6. The identity of the antigen was confirmed using flow cytometry, ELISA, siRNA knockdown, and surface plasmon resonance experiments.

Siglec-6 is not expressed by hematopoietic stem cells; expression is believed to be limited to the placenta, mast cells, and exhausted B cells.

“Siglec-6 was broadly expressed in CLL and could be a potential target for antibody-based therapeutic interventions,” the study authors concluded. “Our study reaffirms the utility of post-alloHSCT antibody drug and target discovery.”

Reference

  1. Chang J, Peng H, Shaffer BC, et al. Siglec-6 on chronic lymphocytic leukemia cells is a target for post-allogeneic hematopoietic stem cell transplantation antibodies. Cancer Immunol Res. 2018;6:1008-1013. doi: 10.1158/2326-6066.CIR-18-0102

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs